Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease
Open Access
- 16 August 2011
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 155 (2) , 263-267
Abstract
Summary: Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3 years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8 h compared to placebo (P = 0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL‐selectin; however, participants with rebound pain had higher sL‐selectin within 24 h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL‐selectin is a promising biomarker of ACS therapy.Keywords
This publication has 19 references indexed in Scilit:
- A Short Course of Prednisone in the Management of Acute Chest Syndrome of Sickle Cell DiseaseJournal of Pediatric Hematology/Oncology, 2010
- Increased levels of the inflammatory biomarker C‐reactive protein at baseline are associated with childhood sickle cell vasocclusive crisesBritish Journal of Haematology, 2010
- A recommitment to sickle cell disease researchBlood, 2008
- A Single-Institution Experience With Treatment of Severe Acute Chest Syndrome: Lack of Rebound Pain With Dexamethasone Plus Transfusion TherapyJournal of Pediatric Hematology/Oncology, 2008
- Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemiaThrombosis Research, 2008
- The intriguing contribution of white blood cells to sickle cell disease – a red cell disorderBlood Reviews, 2004
- Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiologyThe Lancet, 2003
- Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.1999
- Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease.1998
- High-Dose Intravenous Methylprednisolone Therapy for Pain in Children and Adolescents with Sickle Cell DiseaseNew England Journal of Medicine, 1994